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Treatment of mucosal leishmaniasis with amphotericin B lipid 
complex (ABLC)
Dear Editor
Mucosal leishmaniasis (ML) is a disease that can destroy cartilages, the 
pharynx and larynx, as well as bone structures of the face1. The treatment of ML 
is essentially based on the use of antimonial pentavalent. However, this drug has 
several adverse effects (AEs) and contraindications. Amphotericin B has been an 
alternative to antimonial pentavalent, mainly the liposomal formulation (L-AMB)2. 
However, the cost of the drug can be prohibitive to developing countries, and the 
ideal dose has not yet been established. Amphotericin B lipid complex (ABLC) 
is another lipid formulation of amphotericin B, with less nephrotoxicity than the 
deoxycholate formulation and is less expensive than L-AMB. As far as we know, 
this is the first report on a series of cases on the treatment of ML with ABLC. We 
report 13 cases of patients with ML treated with ABLC from a Brazilian cohort 
from January 2000 to July 2015. 
Patients with confirmed ML older than 18 years and followed-up for at least 
6 months were included in the cohort. Patients without confirmation of ML and 
refusal of treatment were excluded. The diagnosis of ML included the amplification 
of Leishmania spp. DNA in tissue samples by molecular techniques, isolation of 
parasites in cultures, or the finding of typical structures during the histological 
examination or in immunohistochemistry tests. Otorhinolaryngological evaluations 
were performed in all patients. Pentavalent antimonial was the first option of 
treatment. Lipid formulations were indicated after pentavalent antimonial failure, 
appearance of side effects or the presence of a contraindication for the pentavalent 
antimonial use. The choice of the lipid formulation of amphotericin B was a medical 
decision and in 13 cases ABLC (1–4 mg/kg/day to achieve a cumulative dose of 
1,500 to 2,500 mg) was administered. 
Cure, failure and recurrence episodes were previously defined3. AEs associated 
with the treatment of ML were analyzed during the hospitalization period. Acute 
kidney injury (AKI) was defined according to the AKIN criteria4. 
The median age of the patients was 58 [IQR 55-65] years old and 53.8% of 
patients were men. Most patients presented symptoms for more than 5 years (65.4%). 
All species identified were L. braziliensis. Treatment of all patients with ML was 
performed in the hospital with a median hospitalization time of 25 [IQR 19-28] 
days. ABLC was associated with several infusion-related AEs (Table 1). The cure 
rate of the group that used ABLC was 46.1%, and 1 case considered previously 
cured has recurred. The dosage of ABLC varied from 1 to 4.5 mg/kg (average 
2.6 mg/kg). The mean cumulative dose was 1,253 mg (planned cumulative dose 
of 1,500 to 2,500 mg). 
Data on ABLC in the treatment of ML have not been published in the literature, 
although this drug has been used since the 1990s for the treatment of visceral 
leishmaniasis5. The results showed a success rate limited to 46.1% (6/13) and a 
relapse rate of 7.7%. Other drugs have shown clinical cure rates between 71.0% 
and 77.0% of the cases1. Recurrence with the use of antimonial pentavalent is 
around 22%1. However, the daily recommended dose was low, not achieving the 
adequate cumulative dose. The treatment of ML is still far from the ideal because 
the best performing drugs for this condition have numerous AEs, and drugs that 
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are safer to use have lower efficacy. ABLC presented a 
low rate of cure and several side effects, suggesting that 
the use of this drug is questionable.
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Table 1 - Clinical and laboratorial findings of 13 patients with mucosal leishmaniasis.
N Sex Age Weight Site Previous treatment
Interruption 
due to side 
effects
Phebitis Infusion 
side effects AKI
CrCl* 
(mL/min)
Electrolyte 
distur-
bance
Myelo-
toxicity
Dosage 
(mg/kg/d) Cure
1 M 52 93 Palate and pharynx No Yes Yes
Sweat, 
nausea, 
chest pain
No 77.2 No Yes 3.0 No
2 F 72 63 Nasal 
septum No Yes Yes Chest pain No 35 Yes No 1.7 No
3 M 58 95 Nasal 
septum Yes No Yes
Fever, 
sweat, 
nausea
No 108.2 Yes No 1.1 Yes
4 F 55 64 Nasal 
septum Yes Yes No Chills No 42.8 No No 3.1 No
5 M 64 72 Nasal 
septum Yes Yes No
Nausea 
and vomits No 71.8 No No 2.8 No
6 M 71 44
Palate, 
pharynx and 
larynx
No No Yes  No 60.2 Yes No 4.5 Yes
7 F 53 45 Nasal 
septum No Yes No
Nausea 
and vomits No 54.4 Yes No 2.0 No
8 F 53 45 Nasal 
septum No No Yes
Nausea 
and vomits, 
chest pain
Yes 79.5 Yes No 2.1 Yes
9 M 57 74 Nasal 
septum Yes No No  No 62.7 No No 2.0 Yes
10 F 61 58 Palate and pharynx Yes Yes No Fever No 23.8 No No 4.0 No
11 F 65 49
Palate, 
pharynx and 
larynx
Yes No No  No 51.6 No No 3.1 Yes
12 M 57 74 Nasal 
septum Yes No No  No 43.3 Yes No 2.0 Yes
13 Male 76 62
Nasal 
septum and 
pharynx
Yes No Yes  No 52.3 No No 2.4 No
*creatinine clearance
